“Data from the generalized anxiety disorder phase two is anticipated in the early part of 2027.”

In context

“schizophrenia, with the 75-milligram dose cleared and 100 milligrams currently being assessed. Further dose escalation is planned until a tolerability threshold is reached. Based on the favorable profile with 75 milligrams and the potential to move the dose even higher, emeraclidine will be moving forward in development as both a monotherapy and adjunctive treatment for schizophrenia. Dose ranging in elderly patients is also ongoing, which will support development plans in psychosis related to Alzheimer's, Parkinson's, and dementia with Lewy bodies. Phase two studies across all indications will begin after the completion of multiple ascending dose evaluation. The phase two study for ABBV 932 in bipolar depression is nearing completion, and data is expected around the middle of this year. Data from the generalized anxiety disorder phase two is anticipated in the early part of 2027. This year, data from two additional cohorts from a phase two study evaluating bradicilacin in major depressive disorder will help inform our development strategy and phase three plans. This short-acting psychedelic demonstrated very strong durable efficacy in a preliminary phase two study. Based on this emerging profile, reticilacin has the potential to become a groundbreaking new treatment in depression. Moving to other areas of our pipeline, in obesity, data will be available this year from two ongoing phase one studies evaluating our long-acting amylin analog ABBV 295 in overweight and obese patients. Results will guide our phase two program, which is expected to begin near the end of this year. In aesthetics, the regulatory application for our rapid-onset short-acting toxin Trenebody”